Johnson and Johnson

Johnson & Johnson (JNJ) – Will JNJ continue its downward trajectory?

in , , on September 26, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Johnson & Johnson (JNJ)

JNJ is one of the strong player in pharmaceutical industry. The companies in this sector compete based on their key product performance. Any negative impact on the key products can significantly impact the revenue of the companies.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 34

Release Information

  • Price
    :

    $99.00

  • Released
    :

    September 26, 2022

  • Last Updated
    :

    September 29, 2022